These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 31387917)

  • 21. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
    Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
    Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
    Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
    Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
    Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
    Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
    Zorko NA; Bernot KM; Whitman SP; Siebenaler RF; Ahmed EH; Marcucci GG; Yanes DA; McConnell KK; Mao C; Kalu C; Zhang X; Jarjoura D; Dorrance AM; Heerema NA; Lee BH; Huang G; Marcucci G; Caligiuri MA
    Blood; 2012 Aug; 120(5):1130-6. PubMed ID: 22674806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
    Uras IZ; Walter GJ; Scheicher R; Bellutti F; Prchal-Murphy M; Tigan AS; Valent P; Heidel FH; Kubicek S; Scholl C; Fröhling S; Sexl V
    Blood; 2016 Jun; 127(23):2890-902. PubMed ID: 27099147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
    Zhu R; Shirley CM; Chu SH; Li L; Nguyen BH; Seo J; Wu M; Seale T; Duffield AS; Staudt LM; Levis M; Hu Y; Small D
    Leukemia; 2024 Jul; 38(7):1581-1591. PubMed ID: 38811818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
    Wang YG; Liu XH; Liang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.
    Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R
    Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
    Wang R; Li Y; Gong P; Gabrilove J; Waxman S; Jing Y
    Mol Cancer Ther; 2018 Sep; 17(9):1871-1880. PubMed ID: 29959200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
    Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
    Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
    Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.